News | Peripheral Artery Disease (PAD) | July 17, 2017

First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device

Company also announces commencement of international post-market study of Percutaneous Deep Vein Arterialization (pDVA) System

First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device

July 17, 2017 — LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System. The novel, purely percutaneous device is designed for the treatment of end-stage critical limb ischemia (CLI) when all other revascularization efforts have been exhausted. The first patient was treated on July 5, 2017 at Metro Health - University of Michigan Health by Jihad A. Mustapha, M.D., FACC, FSCAI.

The feasibility study is a multi-center, prospective, single-arm study to be conducted at three U.S. centers encompassing 10 “no-option” CLI patients. Endpoints include amputation-free survival at one month, patency, limb salvage and wound healing. Subjects will be followed out to two years.  This clinical trial is the initial step towards a U.S. approval pathway for the LimFlow System.

“The only other disease with worse life expectancy than CLI is pancreatic cancer. Because of the mortality rate associated with amputations due to ischemia, a new approach to treat CLI is needed now more than ever.  In the LimFlow study, we hope to help patients with no other options that are on their way to amputation” said Mustapha, the study’s primary investigator.

The Paris-based medical device company also announced the initiation of a multicenter, prospective, single-arm post-market surveillance study, which will enroll up to 50 Rutherford Class 5 and 6 “no-option” patients in several CLI centers of excellence in Europe and Asia. Patients will be followed out to one year, and endpoints include amputation-free survival (AFS) and wound healing progression. Data collection is aligned with the U.S. feasibility study, allowing for a large comparable dataset for the use of the LimFlow System in this “no-option” CLI sub-group.

The LimFlow System is designed to restore perfusion to the ischemic foot, which may relieve rest pain, promote chronic wound healing, reduce major amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. It uses proprietary ultrasound-guided catheters and covered nitinol stents to uniquely bypass diseased arteries and divert blood flow into the tibial vein to vascularize the ischemic foot.

For more information: www.limflow.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init